Literature DB >> 10835018

Limitations of vitek GPS-418 cards in exact detection of vancomycin-resistant enterococci with the vanB genotype.

T Okabe1, K Oana, Y Kawakami, M Yamaguchi, Y Takahashi, Y Okimura, T Honda, T Katsuyama.   

Abstract

The susceptibilities of 20 strains of vancomycin-resistant enterococci (VRE) with the vanB genotype obtained by using Vitek GPS-418 cards were compared with those obtained by the broth dilution method of the National Committee for Clinical Laboratory Standards (NCCLS) (approved standard M7-A4) and with those obtained by the agar screen method using bile esculin azide agar containing 6 microgram of vancomycin per ml. Although both the broth dilution and agar screen methods disclosed no discordance, Vitek GPS-418 cards yielded a very major error compared with the results obtained by the reference broth dilution method of the NCCLS. Vitek GPS-418 cards were therefore found to have considerable room for improvement for the accurate detection of vanB VRE strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835018      PMCID: PMC86825          DOI: 10.1128/JCM.38.6.2409-2411.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  [Laboratory-evaluation of antimicrobial susceptibility testings to detect vancomycin-resistant enterococci].

Authors:  N Yamane; S Miyagawa; I Nakasone; F Sakamoto; M Tosaka
Journal:  Rinsho Byori       Date:  1997-04

2.  Evaluation of commercial vancomycin agar screen plates for detection of vancomycin-resistant enterococci.

Authors:  K G Van Horn; C A Gedris; K M Rodney; J B Mitchell
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

3.  Control of a nosocomial outbreak of vancomycin resistant Enterococcus faecium in a paediatric oncology unit: risk factors for colonisation.

Authors:  C Nourse; H Murphy; C Byrne; A O'Meara; F Breatnach; M Kaufmann; A Clarke; K Butler
Journal:  Eur J Pediatr       Date:  1998-01       Impact factor: 3.183

4.  Comparison of eight methods to detect vancomycin resistance in enterococci.

Authors:  H P Endtz; N Van Den Braak; A Van Belkum; W H Goessens; D Kreft; A B Stroebel; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

5.  VanD-type glycopeptide-resistant Enterococcus faecium BM4339.

Authors:  B Perichon; P Reynolds; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  [Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci].

Authors:  I H Saraiva; R N Jones; M Erwin; H S Sader
Journal:  Rev Assoc Med Bras (1992)       Date:  1997 Jul-Sep       Impact factor: 1.209

7.  VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405.

Authors:  M Fines; B Perichon; P Reynolds; D F Sahm; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-08-06       Impact factor: 17.586

9.  Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey.

Authors:  A M Goetz; J D Rihs; M M Wagener; R R Muder
Journal:  Am J Infect Control       Date:  1998-12       Impact factor: 2.918

10.  Vancomycin-resistant-enterococci--colonization of 24 patients on a pediatric oncology unit.

Authors:  F Schuster; U B Graubner; I Schmid; M Weiss; B H Belohradsky
Journal:  Klin Padiatr       Date:  1998 Jul-Aug       Impact factor: 1.349

View more
  2 in total

1.  Validation of VITEK 2 version 4.01 software for detection, identification, and classification of glycopeptide-resistant enterococci.

Authors:  Marianne Abele-Horn; Leif Hommers; René Trabold; Matthias Frosch
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 2.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.